FirsthandHealth
medRxiv PreprintsInternational18 November 2026

Plasma Alzheimer''s assays agree on level but much less on individual rates of change

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

INTRODUCTION: Serial plasma testing is proposed for monitoring Alzheimer's disease and for trials, but its reliability for a person's rate of change is unknown. METHODS: In 393 ADNI participants with three plasma samples over a median 5.0 years, 15 measures of five biomarkers were assayed on aliquots of the same samples, separating shared change from assay-specific variation at each sampling occasion. Results were tested in 1,093 A4/LEARN participants. RESULTS: Assays agreed well on cross-sectional levels (intraclass correlation 0.75--0.95 for pTau217, pTau181, GFAP, NfL) but less on individua
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.